Skip to main content

Table 4 Treatment for SLE and PAH

From: Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients

  SLE-PAH n = 21 SLE-nPAH n = 44 P-value
Corticosteroids, n (%) 17 (85) 44(100) 0.009
Antimalarial agents, n (%) 17 (85) 44(100) 0.009
Immunosuppressants, n (%)
 Azathioprine 8 (40) 25 (56.8) 0.212
 Mycophenolate 1 (5) 13 (29.5) 0.028
 Cyclophosphamide 3 (15) 25 (56.8) 0.002
 Methotrexate 11 (55) 19 (43.2) 0.380
PAH treatment
 Sildenafil, n (%) 12 (57.1)  
 Bosentan, n (%) 10 (47.6)  
 Cyclophosphamide IV, n (%) 10 (47.6)  
 Methylprednisolone IV, n (%) 8 (38.1)  
 Oral anticoagulants, n (%) 13 (65)  
  1. nPAH no PAH, PAH pulmonary arterial hypertension, SLE systemic lupus erythematosus